KR102566237B1 - 사이클로올레핀 치환된 헤테로방향족 화합물 및 그의 용도 - Google Patents

사이클로올레핀 치환된 헤테로방향족 화합물 및 그의 용도 Download PDF

Info

Publication number
KR102566237B1
KR102566237B1 KR1020207009621A KR20207009621A KR102566237B1 KR 102566237 B1 KR102566237 B1 KR 102566237B1 KR 1020207009621 A KR1020207009621 A KR 1020207009621A KR 20207009621 A KR20207009621 A KR 20207009621A KR 102566237 B1 KR102566237 B1 KR 102566237B1
Authority
KR
South Korea
Prior art keywords
compound
formula
alkyl
independently selected
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207009621A
Other languages
English (en)
Korean (ko)
Other versions
KR20200052321A (ko
Inventor
웨이-구오 수
광시우 다이
쿤 시아오
Original Assignee
허치슨 메디파르마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허치슨 메디파르마 리미티드 filed Critical 허치슨 메디파르마 리미티드
Publication of KR20200052321A publication Critical patent/KR20200052321A/ko
Application granted granted Critical
Publication of KR102566237B1 publication Critical patent/KR102566237B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020207009621A 2017-09-07 2018-09-07 사이클로올레핀 치환된 헤테로방향족 화합물 및 그의 용도 Active KR102566237B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710801364.3 2017-09-07
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途
PCT/CN2018/104531 WO2019047909A1 (en) 2017-09-07 2018-09-07 HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE

Publications (2)

Publication Number Publication Date
KR20200052321A KR20200052321A (ko) 2020-05-14
KR102566237B1 true KR102566237B1 (ko) 2023-08-14

Family

ID=65634832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009621A Active KR102566237B1 (ko) 2017-09-07 2018-09-07 사이클로올레핀 치환된 헤테로방향족 화합물 및 그의 용도

Country Status (19)

Country Link
US (3) US11414390B2 (enExample)
EP (1) EP3679020A4 (enExample)
JP (2) JP7273030B6 (enExample)
KR (1) KR102566237B1 (enExample)
CN (6) CN109467538A (enExample)
AR (1) AR112794A1 (enExample)
AU (1) AU2018329047B2 (enExample)
CA (1) CA3073782A1 (enExample)
CL (1) CL2020000553A1 (enExample)
EA (1) EA202090653A1 (enExample)
IL (1) IL272923B2 (enExample)
MX (1) MX2020002505A (enExample)
PE (1) PE20200727A1 (enExample)
PH (1) PH12020500408A1 (enExample)
SG (1) SG11202001642WA (enExample)
TW (1) TWI816693B (enExample)
UA (1) UA129118C2 (enExample)
WO (1) WO2019047909A1 (enExample)
ZA (1) ZA202001448B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
EP4653429A1 (en) 2017-09-07 2025-11-26 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
CN116209655A (zh) * 2020-11-09 2023-06-02 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
CN118355008A (zh) * 2022-01-11 2024-07-16 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044469A (zh) * 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
JP2016523935A (ja) * 2013-07-11 2016-08-12 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびその使用方法
WO2017016513A1 (zh) * 2015-07-30 2017-02-02 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物及其使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555154A (en) * 1967-08-16 1971-01-12 Armour Pharma Preparations containing 6 - cycloalkylguanamines and methods for treating inflammatory conditions therewith
US5019574A (en) 1988-09-30 1991-05-28 Chugai Seiyaku Kabushiki Kaisha 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2005115242A2 (en) 2004-05-24 2005-12-08 Equusys, Incorporated Animal instrumentation
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101466670B (zh) * 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US20100035863A1 (en) 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US20100168077A1 (en) * 2007-04-04 2010-07-01 Ucb Pharma, S.A. Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2445886B1 (en) * 2009-06-25 2016-03-30 Amgen, Inc 4-aminoquinoline derivatives as pi3k inhibitors
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2012003283A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
EP2680852A1 (en) * 2011-03-02 2014-01-08 Lead Discovery Center GmbH Pharmaceutically active disubstituted triazine derivatives
MX347241B (es) * 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
EP2755965B1 (en) 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
AU2013336755B2 (en) 2012-10-24 2017-07-20 Basf Se Herbicidal azines
WO2014116594A1 (en) 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
EP3019490B1 (en) * 2013-07-11 2020-06-03 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
EA030428B1 (ru) 2013-08-02 2018-08-31 Аджиос Фармасьютикалз, Инк. Терапевтически активные соединения и способы их применения
HRP20181287T1 (hr) * 2013-11-01 2018-10-05 Novartis Ag Aminoheteroarilbenzamidi kao inhibitori kinaze
EP3151833A4 (en) 2014-06-04 2018-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
WO2015187088A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
EP3383400B1 (en) 2015-12-04 2022-01-05 Les Laboratoires Servier Methods of treatment of malignancies
WO2017096945A1 (zh) * 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件
EP3442947B1 (en) 2016-04-15 2023-06-07 Epizyme, Inc. Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
EP3652184A1 (en) 2017-08-15 2020-05-20 AbbVie Inc. Macrocyclic mcl-1 inhibitors and methods of use
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
RS62796B1 (sr) 2017-09-07 2022-02-28 Eisai R&D Man Co Ltd Pentaciklično jedinjenje

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044469A (zh) * 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
JP2016523935A (ja) * 2013-07-11 2016-08-12 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびその使用方法
WO2017016513A1 (zh) * 2015-07-30 2017-02-02 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物及其使用方法

Also Published As

Publication number Publication date
AU2018329047A1 (en) 2020-03-12
UA129118C2 (uk) 2025-01-22
CN109467538A (zh) 2019-03-15
EA202090653A1 (ru) 2021-02-03
ZA202001448B (en) 2024-11-27
CN117797156A (zh) 2024-04-02
IL272923B2 (en) 2023-06-01
JP7273030B6 (ja) 2024-02-15
CA3073782A1 (en) 2019-03-14
CN111132967B (zh) 2023-08-04
KR20200052321A (ko) 2020-05-14
EP3679020A1 (en) 2020-07-15
IL272923A (en) 2020-04-30
CN117257809A (zh) 2023-12-22
EP3679020A4 (en) 2021-05-05
US12234211B2 (en) 2025-02-25
JP7603740B2 (ja) 2024-12-20
US20220372005A1 (en) 2022-11-24
US20210163426A1 (en) 2021-06-03
AR112794A1 (es) 2019-12-11
JP2020533319A (ja) 2020-11-19
CN111132967A (zh) 2020-05-08
CN116999441A (zh) 2023-11-07
BR112020004563A2 (pt) 2020-09-08
PE20200727A1 (es) 2020-07-23
US20210363115A2 (en) 2021-11-25
JP2023103290A (ja) 2023-07-26
US20250223267A1 (en) 2025-07-10
SG11202001642WA (en) 2020-03-30
AU2018329047B2 (en) 2023-09-07
JP7273030B2 (ja) 2023-05-12
PH12020500408A1 (en) 2021-03-01
WO2019047909A1 (en) 2019-03-14
TWI816693B (zh) 2023-10-01
TW201912632A (zh) 2019-04-01
CN117024363A (zh) 2023-11-10
MX2020002505A (es) 2020-07-20
NZ762447A (en) 2023-09-29
CL2020000553A1 (es) 2020-08-07
US11414390B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
JP7603740B2 (ja) シクロオレフィン置換複素芳香族化合物およびそれらの使用
JP2017031207A (ja) 置換６，６−縮合窒素複素環化合物及びその使用
JP2019513781A (ja) アクチビン受容体様キナーゼの阻害剤
AU2013272701A2 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
CN121194980A (zh) 三环类化合物及其用途
TW202140488A (zh) 雜芳基雜環化合物及其用途
KR20230167347A (ko) 트리사이클릭 화합물 및 이의 용도
WO2020228823A1 (en) Novel amide compounds and uses thereof
CN112047877A (zh) 新型酰胺类化合物及其用途
HK40027076A (en) Cycloolefin substituted heteroaromatic compounds and their use
BR112020004563B1 (pt) Compostos heteroaromáticos substituídos por ciclo-olefina e seu uso
HK40027076B (zh) 环烯烃取代的杂芳环类化合物及其用途
EA044101B1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение
NZ762447B2 (en) Cycloolefin substituted heteroaromatic compounds and their use
CN119816499A (zh) 三嗪类化合物及其用途
WO2025148870A1 (zh) Ras抑制剂
WO2021136464A1 (en) Novel amide compounds and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200402

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210527

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230302

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230701

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230808

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230809

End annual number: 3

Start annual number: 1

PG1601 Publication of registration